Unique Therapeutic Approaches for Targeting Epigenetic Machinery in T-cell Lymphoma by Cogan, Jacob & Amengual, Jennifer E.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books






Unique Therapeutic Approaches 
for Targeting Epigenetic 
Machinery in T-cell Lymphoma
Jacob Cogan and Jennifer E. Amengual
Abstract
Growing knowledge on T-cell lymphoma (TCL) biology has led to the under-
standing that TCLs harbor derangements in proteins modulating epigenetic control. 
Some such derangements include mutations in TET2, IDH2, DNMT3A, EP300, and 
CBP. In addition, overexpression of epigenetic modifiers such as EZH2 also exists in 
the absence of mutations. HDAC inhibitors are approved for use in relapsed T-cell 
lymphoma. There may be unique methods to targeting epigenetic derangements 
using new agents such as DNMT, EZH2, IDH, and BET inhibitors to name a few. In 
this chapter, we will review and explore unique methods for therapeutic targeting 
of epigenetic machinery for TCL.
Keywords: T-cell lymphoma, epigenetics, EZH2, DNMT3A, IDH2, TET2, BET, 
EP300, CBP, DOT1L
1. Introduction
Peripheral T-cell lymphomas (TCL) are a diverse group of non-Hodgkin lym-
phomas that tend to have aggressive courses and poor prognoses. TCLs account for 
10–15% of all non-Hodgkin lymphomas. Common subtypes are anaplastic large cell 
lymphoma (ALCL), angioimmunoblastic T-cell lymphoma (AITL), cutaneous T-cell 
lymphoma (CTCL), and peripheral T-cell lymphoma NOS (PTCL-NOS). Even more 
rare subtypes include adult T-cell leukemia/lymphoma (ATLL) and natural killer/T-
cell lymphoma (NKTCL). The diagnosis of these conditions can be challenging, as 
the largest group of these conditions – PTCL-NOS – cannot currently be further 
categorized beyond that point [1]. Similarly, the approach to treating TCLs has 
generally been empiric and homogenous, rather than specific and targeted to the 
particular subtype.
TCL patients frequently do not respond well to chemotherapy. The median 
time to relapse or progression after primary therapy was 6.7 months in a sample of 
153 patients with PTCL-NOS, AITL, and ALCL, three of the most common TCL 
subtypes [2]. Further, median overall survival and progression free survival after 
relapse or progression in this sample was 5.5 and 3.1 months, respectively. Given 
this poor response to chemotherapy, the subsequent lack of candidacy for stem cell 
transplantation in most TCL patients given this poor response, and the tendency 
of TCL patients to develop resistance to chemotherapy, optimal therapies for this 
population remain undefined. Clinical trials are thus often the recommended first-
line treatment for these patients.
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Limitations in the specificity of treatment of TCL may be related to prior lack 
of insight into the genetics and molecular underpinnings of these malignancies. 
However, as understanding of the genetics of these diseases advances, therapy 
targeting epigenetic modifiers and transcriptional dysregulation have emerged as a 
target for TCL therapy [1, 3]. Epigenetic modulators have been found to be widely 
mutated in TCLs, and are thought to play a central role in these diseases. The heri-
tability of epigenetic profiles across cell lines, and the consistency with which this 
process is aberrant in TCLs makes targeting epigenetic modifiers an area of promise 
in treating these particularly resistant conditions [4].
Epigenetics refers to aspects of chromatin biology that affect gene expression 
without altering DNA sequence. Chromatin is comprised of DNA wrapped around 
a core of four types of histone proteins, forming nucleosomes. The ability of the 
transcriptional machinery to access chromatin determines gene expression. This 
accessibility is determined by posttranslational modifications of the components 
of the nucleosome complex, such as methylation and acetylation of DNA and 
histones. Given the inherently plastic and reversible nature of epigenetic modifi-
cations, they have emerged as an appealing therapeutic target, in contrast to the 
more fixed nature of genetic alterations. Further, epigenetic regulators often have 
enzymatic activities or binding domains that lend themselves well to small mol-
ecule inhibition [3].
Epigenetic abnormalities targeted in TCLs tend to be related to methylation 
and acetylation of histones and DNA. Histone deacetylase (HDAC) inhibitors 
were the first approved epigenetic therapy for TCL. HDACs tend to be recruited by 
oncoproteins to support repressive malignant gene expression [3]. The U.S. FDA has 
approved three HDAC inhibitors for use in relapsed or refractory TCLs. Vorinostat, 
an oral agent, was approved for relapsed/refractory CTCL in 2006, with romidep-
sin—an IV agent—following shortly after in 2009 [5]. Romidepsin and belinostat 
were also approved for the treatment of relapsed/refractory peripheral TCLs 2011 
and 2014, respectively. Adverse effects include cytopenias and gastrointestinal 
symptoms. In addition, romidepsin can lead to EKG changes that may be clinically 
significant in patients with pre-existing cardiac disease. Interestingly, the clinical 
benefit derived from HDAC inhibitors in TCLs have not shown the same efficacy 
Table 1. 
Pre-clinical studies of novel epigenetic inhibitors in T-cell lymphoma.
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in B-cell lymphomas, further underscoring the importance of pursuing this treat-
ment paradigm for TCLs. Romidepsin, belinostat and vorinostat are currently being 
studied in combination with conventional chemotherapies [6], such as CHOP [7, 8], 
gemcitabine [9] and ifosfamide-containing regimens [10].
Given the success of HDAC inhibitors in TCLs, much research has been dedicated 
towards elucidating other epigenetic targets for TCL therapy (Tables 1 and 2). 
Candidates have included DNA methyltransferases (DNMTs), the ten-eleven 
Figure 1. 
(A) Histone acetylation makes chromatin more accessible for transcription, while histone deacetylation 
makes chromatin more compact and less transcriptionally active. Histone acetylation is mediated by histone 
acetyltransferases, such as CBP and EP300; histone deacetylation is mediated by histone deacetylases (HDACs). 
Inhibitors of CBP, EP300, and HDACs have all shown promise in treating TCLs. BET proteins recognize 
acetylated histones and promote transcription at related DNA regions, and can be targeted by BET inhibitors. 
By contrast, methylation of histones renders DNA transcriptionally inactive, while demethylation of histones 
increases DNA receptiveness to transcription. EZH2 and DOT1L are histone methylators, and are targets in 
TCL therapy as well. (B) DNA methylation is associated with transcriptional repression, while de-methylated 
DNA is more transcriptionally active. TET2 promotes DNA demethylase activity, and IDH2 regulates TET2. 
TET2 and IDH2 can both be targeted in TCL treatment. Additionally, a major category of TCL therapy involves 
inhibitor of DNA methyltransferases (DNMTs), which render chromatin more transcriptionally inactive.
Table 2. 
Clinical trials of novel epigenetic inhibitors in T-cell lymphoma.
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translocation (TET) family of proteins, isocitrate dehydrogenase (IDH) enzymes, 
bromodomain and extra-terminal (BET) proteins, enhancer of zeste homolog 2 
(EZH2), cyclic AMP-response element binding, binding protein (CBP) and E1A 
binding protein p300 (EP300), and disruptor of telomeric silencing 1-like (DOT1L) 
(Figure 1). Further, it has been postulated that combination therapy of different 
epigenetic modulators may have added utility in TCL treatment. Tumor suppressors 
are often down regulated by abnormal histone deacetylation and/or DNA methyla-
tion. By combining HDAC inhibitors and DNMT inhibitors, synergy may be achieved 
to relieve this abnormal transcriptional repression [11]. Thus, epigenetic combina-
tion therapy may represent a new paradigm for the treatment of TCLs [5, 12]. In this 
manuscript, we will review the TCL subtypes and relevant documented mutations, 
survey the literature regarding novel epigenetic therapies for TCL, and discuss future 
directions for this therapeutic strategy.
2. T-cell lymphoma subtypes
2.1 Anaplastic large cell lymphoma (ALCL)
Anaplastic large cell lymphoma (ALCL) represents up to 32% of TCLs in 
North America, and about 2.4% of NHLs [5]. It is more common in men (2:1 male: 
female ratio), and displays a bimodal age distribution, with peaks at age 25 and 
60. ALCL frequently involves the lymph nodes or skin, but can also affect the 
gastrointestinal tract, lung, and bone. Translocations involving the Anaplastic 
Lymphoma Kinase (ALK) are common in ALCL, with t(2,5) translocations 
occurring in 50% of cases, and leading to a Nucleophosmin-ALK (NPM-ALK) 
fusion protein. This protein induces a number of oncogenic signaling pathways, 
leading to malignant transformation of T-cells [13]. ALK status is important for 
prognosis, with ALK+ positive displaying a 70% 5-year survival, while ALK- 
patients have a 49% survival rate [5]. Chemotherapy is the first line treatment 
for this disease, and crizotinib, an ALK tyrosine kinase inhibitor, can be used in 
chemotherapy-resistant disease ALK+ ALCL. However, resistance to crizotinib 
frequently develops, motivating pursuit of other treatment strategies. DNA meth-
ylation profiling of five ALCL patients displayed similar patterns of methylation 
in all samples, regardless of ALK status. This abnormal methylation was noted in 
genes involved in T-cell differentiation and immune response [14], suggesting a 
role of epigenetic derangements in driving ALCL development. Inhibitors of BET 
proteins, which recognize acetylated histones and recruit transcription factors to 
these regions, have been used in pre-clinical models to treat ALCL, described later 
in this review.
2.2 Angioimmunoblastic T-cell lymphoma (AITL)
Angioimmunoblastic T-cell lymphoma (AITL) comprises 20% of TCLs and 1% 
of all NHLs [15]. Patients tend to be diagnosed with advanced stage disease, and 
have a median survival of less than 3 years. AITLs are unique in their gene expres-
sion pattern, with mutations in genes responsible for epigenetic modifications – 
particularly DNA methylation – emerging as particularly commonplace. In a study 
of 85 AITL patients, 65 (76%) had TET2 mutations, 43 of which displayed two or 
three TET2 mutations, indicating strong selective pressure for TET2 abnormalities 
in AITL. Twenty-eight patients (33%) had DNMT3 mutations, and 17 (20%) had 
mutations in IDH2. Of note, all but two of the patients in this sample with DNMT3 
and IDH2 mutations also had TET2 mutations. Mutations in these specific types of 
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epigenetic modulators are more commonly seen in myeloid malignancies than in 
other lymphomas. This could help explain the poor outcomes AITL patients have 
after treatment with chemotherapy regimens developed against BCLs. The multi-
step tumorigenesis model for AITL hypothesizes that early mutations in epigenetic 
modifiers interact with late cooperative mutations to enable malignant transforma-
tion [5]. As such, TET2, DNMT3, and IDH2, among other epigenetic modulators, 
have emerged as therapeutic targets in AITL.
2.3 Cutaneous T-cell lymphoma (CTCL)
Cutaneous T-cell lymphoma (CTCL) includes mycosis fungoides (MF), Sezary 
syndrome (SS), and other related lymphoproliferative disorders that originate in 
the skin. CTCL is a male-predominant disease (1.7:1.0 M:F ratio), has a median 
age of diagnosis in the mid-1950s, and is more common in African Americans [5]. 
MF tends to present with patches, plaques, tumors, and ulcers, while SS presents 
with exfoliative erythroderma, lymphadenopathy, and circulating Sezary cells. 
The prognosis of these patients generally correlates with the extent of cutaneous 
and systemic involvement, with MF displaying an 88% 5-year survival and SS 
patients demonstrating a 5-year survival of 24%. Currently available therapies have 
a success rate of 30–50%, and relapses are common [5, 11]. Epigenetics have been 
important in improving diagnoses of these conditions, with detection of promoter 
hypermethylation of chemokine-like CMTM2 proving sufficient to distinguish SS 
from erythrodermic inflammatory dermatosis [16]. As mentioned earlier, CTCL 
was the first malignancy for which HDAC inhibitors were approved. One such 
agent, romidepsin, showed an overall response rate (ORR) of 35% and complete 
response in 6% when used as monotherapy in relapsed/refractory CTCL patients 
[11]. Currently, a topical HDAC inhibitor for use in early stage CTCL is underway 
with promising results [17]. There is thought that CTCLs may be susceptible to 
additional epigenetic modifiers. SS has also been shown to have a high prevalence 
of methylation abnormalities [4]. TET2 mutations are one of the early genetic 
abnormalities in SS, and mutations in isocitrate dehydrogenase (IDH) have been 
described as well [18].
2.4 Adult T-cell leukemia/lymphoma (ATLL)
ATLL is associated with the human T-cell lymphotropic virus-1 (HTLV-1). The 
virus—endemic to southwestern Japan, the Caribbean, and Central Africa—is 
transmitted by blood transfusions, needle sharing, sexual intercourse, and 
breastfeeding. HTLV-1 immortalizes human T-cells, and was the first retrovirus 
found to be directly associated with malignancy. ATLL occurs in 2.5% of carri-
ers in endemic areas, with growing rates of prevalence in non-endemic areas. 
Subtypes include smoldering, chronic, lymphoma, and acute ATLL, with 4-year 
survival rates ranging from 63% for smoldering to 5% for acute. Chemotherapy 
plus central nervous system prophylaxis is the current first-line treatments for 
ATLL, with some electing to add antiviral therapy, though virus eradication does 
not necessarily lead to improved survival [5]. As a result, attention has turned 
towards understanding the genetic and epigenetic factors involved in causing 
and maintaining malignant disease in HTLV-1 infected T-cells. ATLL cells display 
H3K27me3 hypermethylation, a feature mediated by EZH2. EZH2 overexpression 
leads to this histone hypermethylation, leading to silencing of anti-apoptotic path-
ways [19]. It is thought that this reprogramming occurs at an early stage of ATLL 
T-cell development, potentially as a result of the HTLV-1 protein Tax enhancing 
EZH2 promoter activity. Further, 22% of a 27-patient ATLL cohort were found to 
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have EP300 mutations, with smaller numbers demonstrating mutations in TET2 
and DNMT3A [20].
2.5 Natural killer/T-cell lymphoma (NKTL)
Natural killer/T-cell lymphoma (NKTL) constitutes about 11% of TCLs. Prior 
to the 1990s, the rare disease was known as lethal midline granuloma, in which 
destructive midline facial lesions would develop, progressing rapidly to cause patient 
death. Advances in pathology led to recognition that this condition was a neoplasm 
of lymphoid origin [21]. The disease is predominantly seen in males (2:1 M:F), and 
the median age of diagnosis is 50 years old. They can be classified as nodal and 
extranodal, and further as nasal (nose, upper aerodigestive tract; 80% of cases) 
and non-nasal (skin, GI tract, testes, salivary glands; 20% of cases). Additionally, 
peripheral blood involvement is common, and further labels the disease as a lym-
phoma/leukemia subtype. Interestingly, all NKTL lymphoma cells are infected with 
EBV. Detection of the virus is required for diagnosis, and prognosis can be correlated 
with EBV levels as time of diagnosis and variation of levels in response to therapy. 
NKTL is a particularly aggressive condition, with median survival ranging from 
12 months for the nasal subtype to 2 months for the lymphoma/leukemia subtype. 
Concurrent chemoradiation is the mainstay of treatment for NKTL [5], with non-
anthracycline based regimens (such as those containing L-asparaginase) proving 
more effective. While epigenetic therapies have not to this point been utilized in 
treating NKTL, EP300 and EZH2 mutations have been documented, indicating a 
possible role for epigenetic therapy in this disease [22].
2.6 Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS)
Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) constitutes 
both the largest group of TCLs and the least characterized. PTCL-NOS accounts for 
25% of TCLs, and is a diagnosis of exclusion, when the disease does not fit any of 
the other WHO classifications mentioned above. It tends to affect older men, with a 
median age of presentation of 60. Nodal disease is common, though any organ can 
be affected, and about 70% of cases present at advanced stages. PTCL-NOS patients 
tend to be treated with anthracycline-based chemotherapy regimens. Recurrent 
mutations in TET2, IDH2, and DNMT3A have been found in the T-follicular helper 
phenotype of PTCL-NOS. This disease has since been designated as its own entity, 
distinct from the larger group of PTCL-NOS. Overall, PTCL-NOS patients display 
an overall survival rate of 32–45%. The HDAC-inhibitors romidepsin and belinostat 
are approved for relapsed/refractory PTCL-NOS [6].
3. Epigenetic agents targeting histone methylation and acetylation
Epigenetic modification of histones has both documented and emerging thera-
peutic importance in TCL treatment. Histone acetylation is a dynamic process 
comprised of acetylation with lysine acetyltransferases and deacetylation with 
histone deacetylases (HDACs). Acetylation allows for chromatin configurations 
more accessible to transcription, whereas deacetylation generates more compact, 
less transcriptionally active chromatin [3]. The importance of HDAC inhibitors 
have been well documented in TCLs such as CTCL and PTCL-NOS. Transcriptional 
co-activators such as CBP and EP300 are involved in promoting histone acetylation, 
and have been targeted in the treatment of ATLL. Histone methylation, by contrast, 
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alters the ability of DNA-reading proteins to bind to methylated residues, while 
demethylation of histones render associated chromatin more transcriptionally 
active. EZH2 and DOT1L are clinically important histone methylators, relevant to 
the treatment of ATLL and NKTL, among other subtypes.
3.1 Enhancer of zeste homolog 2 (EZH2)
Enhancer of zeste homolog 2 (EZH2) is the enzymatic component of polycomb 
repressor complex 2 (PRC2). PRC2 has documented involvement in cell fate decisions 
by establishing and maintaining transcriptional repression through post-translational 
modifications of histones via EZH1 and 2 [23]. EZH2 trimethylates lysine residue 
27 of histone H3 (H3K27me3), causing down-regulation of genes involved in tumor 
suppression and cell differentiation [24]. Elevated levels of H3K27me3 are thought to 
correlate with the aggressiveness of malignancies such as lymphoma, in addition to 
brain, breast, kidney, lung, and prostate [25]. While EZH2 is thought to be dispen-
sible for normal hematopoiesis, given it is redundancy with EZH1, EZH2 is the PRC2 
component most often implicated in the development of hematological malignancies 
[3]. EZH2 has emerged as a target for T cell lymphoma therapy. Overexpression of 
EZH2 has been noted in ATLL [26] and NKTL [27], in particular.
Several pre-clinical studies have demonstrated utility of EZH2 inhibition in T 
cell lymphoma. GSK126, a commercially available EZH2 inhibitor, was shown to 
decrease cell viability in an in vitro TCL line [28]. In one study, PTEN-inactivated 
cells derived from a TCL mouse model were utilized. High concentrations of 
GSK126 were required to achieve in vitro biological activity, attributed to the high 
levels of L-amino acid transporter 1 (LAT1) in these cells. As opposed to LAT2, 
which is expressed in normal cells, LAT1 is predominantly expressed in malignant 
cells. Such cells with high levels of LAT1 tend to be more resistant to therapeutic 
treatment, as opposed to cells with lower levels. The authors felt that the high 
LAT1 levels likely gave the in vitro TCL cells an enhanced ability to combat chemi-
cal attacks, via mechanisms such as enhanced essential amino acid sequestering 
potential. This observation supports their notion that combination therapy will be 
the most efficacious method to achieving results when using therapies such as EZH2 
inhibitors. This point highlights the importance of utilizing combination epigenetic 
therapies in treating TCLs.
Work performed in our laboratory sought to combine EZH2 and HDAC inhibi-
tors as a means of dual targeting of histone methylation and acetylation. GSK128 
was combined with romidepsin across a large panel of lymphoma cells (N-21). 
Synergy was observed in cell lines with known EZH2 dysregulation including 
ATLL. We found that the combination led to decreased histone methylation and 
increased acetylation as compared to treatment with either drug alone. This in turn 
induced p21 expression leading to caspase 3 and PARP cleavage. The combination 
is safe and effective in mouse models of lymphoma. Synergy could be predicted in 
cell lines, which were enriched in chromatin silencing, gene silencing, epigenetic 
regulation of gene expression and protein acetylation pathways as measured by 
gene set enrichment analysis (GSEA) [29]. Dual targeting of histone modifications 
could be a rational approach for diseases driven by epigenetic derangements.
DZNep, an EZH2 inhibitor, has demonstrated pre-clinical efficacy in ATLL 
and NKTL. In ATLL cell lines, DZNep been shown to deplete levels of both 
EZH2 and BCL2 [26]. The authors demonstrated that, while untreated ATLL 
cells demonstrate decreased levels of micro RNA 181a (miR-181a), ATLL cells 
treated with DZNep showed elevated levels. miR-181a production is modu-
lated by EZH2, and acts as a negative regulator of BCL2 expression. Thus, the 
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inhibitory effects of DZNep on EZH2 results in increased production of miR-
181a, decreased levels of BCL2, and consequently apoptosis. Further, in [27], 
DZNep inhibited growth of NKTL cell lines in an unexpected fashion. These 
authors noted an oncogenic role of EZH2 independent of its methyltransferase 
activity. Cells with mutations in EZH2 that depleted their histone methyltrans-
ferase activity still had oncogenic potential, likely through increased production 
of cyclin D1. DZNep was still able to inhibit growth of these cells as well. This 
indicates that the oncogenicity of EZH2 mutation is more complicated than sim-
ply arising through overactive histone methylation, and that therapies should 
not simply focus on targeting the enzymatic activity of EZH2, but perhaps on 
the production of EZH2 itself.
In humans, DS-3201b, an oral EZH1/2 dual inhibitor, was utilized in a phase 1 
study which included five TCL patients (two ATLL, two AITL, and one PTCL-NOS) 
[24]. Overall response rate (ORR) in TCL patients was 80%, with one complete 
response (CR) and three partial responses (PR). ORR in the entire cohort (15 total 
patients, 10 with other BCLs) was 55%. Adverse events were mainly transient 
hematologic toxicities.
3.2 Histone acetyltransferases (HATs): CBP/EP300
Cyclic AMP-response element binding, binding protein (CBP) and E1A binding 
protein p300 (EP300) are highly related transcriptional coactivators, with 75% 
similarity across their entire length and 63% homology at the amino acid level [19].  
They are known to enhance transcription through linking sequence-specific 
transcription factors to RNA polymerase II. They also facilitate histone acetyla-
tion, which promotes transcription. [13]. CBP and EP300 are two of the most 
frequently mutated histone acetyl transferases in hematologic malignancies [3]. 
Mutations have been documented in CTCL, ATLL, NKTCL, and PTCL-NOS [1, 3, 
20, 30]. They have also been implicated in the actions of viral oncoproteins such 
as HTLV-1 Tax protein [20]. Acetylation of p53 by CBP has been shown to enhance 
the DNA binding ability of p53, and loss of CBP has been shown to cause T-cell 
lymphomagenesis in vitro [31]. In [20], Shah et al. showed that EP300 mutations 
were present in 22% of a North American cohort of 27 ATLL patients. Five EP300-
mutant ATLL cell lines derived from these patients were treated with decitabine, a 
DNMT-inhibitor. All five lines were sensitive to this treatment, and the addition of 
doxorubicin demonstrated synergy.
Drug development has focused on small molecule inhibitors of both CBP and 
EP300. A-485, a combination CBP/EP300 catalytic inhibitor, was evaluated pre-
clinically across a variety of malignant cell lineages. The broadest sensitivity was 
seen in hematological malignancies, including non-Hodgkin’s lymphoma cell lines, 
with markedly less sensitivity observed in cells derived from solid malignancies 
[32]. Histone acetyltransferase inhibitors may be of use in treating TCLs via this 
pathway.
Histone acetyltransferase activators are also in early development. Inactivating 
mutations in HAT enzymes are monoallelic creating a haploinsufficient state of 
acetylation. Lymphomas harboring a multitude of epigenetic abnormalities, such as 
TCLs are poised to capitalize on this relative deficiency. A library of HAT activating 
compounds have demonstrated efficacy across a panel of lymphoma cell lines and 
xenograft mouse model [33]. The compounds demonstrated acetylation of histone and 
p53. In addition, HAT activators demonstrated synergistic cytotoxicity when combined 
with the HDAC inhibitor, romidepsin. Activating HAT enzymes could therefore be 
thought of as activating a tumor suppressor and offers a direct method of targeting 
pathology that drives TCL.
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3.3 Disruptor of telomeric silencing 1-like (DOT1L)
Disruptor of telomeric silencing 1-like (DOT1L) is the only known H3 lysine 79 
(H3K79) methyltransferase in mammals. Genetic silencing of DOT1L has been shown 
to impact mitotic spindle formation and cell cycle progression. Preclinical models 
have shown utility of DOT1L inhibition in AML. Mutations in Mixed-lineage leuke-
mia (MLL) genes, which encode for a family of histone methyltransferases, have been 
linked to AML (MML1 mutations) and BCLs (MLL2 mutations). The DOT1L con-
taining complex is a frequent translocation partner of MLL fusions in MLL-associated 
leukemias. Consequently these leukemias have been shown to have atypical H3K79 
methylation patterns. Incidentally, AML models carrying recurrent mutations in 
IDH 1/2 and DNMT3A have also been shown to be susceptible to DOT1L inhibitors. 
Pinometostat (EPZ-5676), a recently developed DOT1L inhibitor, is currently in 
phase 1 trials of advanced hematologic malignancies. Given the promising findings of 
DOT1L inhibition in MLL-associated leukemias, and the efficacy of DOT1L inhibi-
tors in AML models with mutations in epigenetic regulators typical of TCLs, there 
may be promise in using DOT1L inhibitors in TCLs as well. Thus far, pinometostat 
has been shown to decrease cell viability in PTEN-inactivated TCL mouse model cells, 
which have also been utilized in pre-clinical studies of EZH2 inhibitors [3, 34, 35].
4. Epigenetic agents targeting DNA methylation
The regulation and maintenance of DNA methylation plays a key role in cellular 
differentiation and genome stability. A dynamic process of DNA methylation and 
demethylation at the carbon-5 position of cytosine nucleotides contributes to the 
epigenetic milieu of any given cell. DNA methyltransferases such as DNMT3A and 
DNMT3B are responsible for de novo DNA methylation, while DNMT1 handles 
maintenance methylation. Conversely, the TET family of proteins handles cytosine 
demethylation. In contrast to histone acetylation, where an acetylated state leads to 
more transcriptionally active chromatin, methylated cytosine residues tend to be asso-
ciated with transcriptional repression. On the other hand, chromatin without cytosine 
methylation is more transcriptionally active [3]. Abnormalities in DNA methylation 
have been found to be important in AITL, CTCL, PTCL-NOS, and ALCL.
4.1 DNMT3
DNMT3A, responsible for de novo DNA methylation, is known to be mutated 
in many hematological malignancies. Azacitidine (5-AZA) and decitabine, two 
DNMT3A inhibitors, are approved for use in myelodysplastic syndromes and 
AML. They are nucleoside analogues which incorporate into newly synthesize 
DNA and RNA strands and subsequently inhibit DNMTs irreversibly. This results 
in decreased DNA methylation, and consequently, daughter cells likely do not 
inherit the aberrant methylation pattern. Given the prevalence of DNMT3A 
mutations in AITL, utilizing DNMT3A inhibitors in this disease has been a focus 
of much recent research. In a study conducted in France by Delarue [36], 19 
patients with relapsed/refractory peripheral TCL were treated with subcutane-
ously administered 5-AZA. The overall response rate for the entire study popula-
tion was 55% (10/19). Twelve of the 19 patients had AITL and the ORR for these 
patients was 75% (9/12). Five of the AITL patients achieved CR, and only 2 of the 
9 total responders had experienced progression at the time of analysis. Notably, 8 
of the AITL patients had documented TET2 mutations, and all of these patients 
responded to therapy. 5-AZA treatment elicited no response in 6 of the remaining 
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7 patients in the study with other TCL subtypes, with the only responder relaps-
ing after cycle 2 of treatment.
PTCL-NOS commonly displays mutations in genes involved in histone meth-
ylation and acetylation. The presence of histone modifier gene mutations was 
associated with decreased progression-free survival in a cohort of 125 PTCL-NOS 
patients. PTCL-NOS cells were shown to experience growth inhibition when treated 
with a HDAC inhibitor, chidamide, and decitabine, both in vitro and in vivo [30]. 
Dual therapy enhanced the interaction of KMT2D with the transcription fac-
tor PU.1, consequently inactivating the MAPK, which tends to be constitutively 
activated in TCL. PU.1 interact with DNMTs to control hematopoiesis and suppress 
leukemia, and KMT2D is a histone modifier.
Combination therapy involving DMNT3A inhibitors has also shown promise. 
Transformed CTCL lines were exposed to combination of a DNMT-inhibitor 
(decitabine or 5-AZA) and an HDAC inhibitor (belinostat, panobinostat, romidep-
sin, or vorinostat), with induction of apoptosis in all lines treated [12]. Combination 
therapy with decitabine and belinostat also induced significant growth delay in an 
in vivo mouse model, compared to mice treated with single agent therapy. Gene 
expression analysis showed that, as opposed to the 138 genes modulated by romidep-
sin monotherapy, combination therapy led to modulation of an additional 390 
genes, with many involved in apoptosis and cell cycle arrest. These findings further 
elucidate the molecular basis of the synergism elicited by combination therapy.
Another study utilized a combination of romidepsin and 5-AZA in cell lines 
from SS patients. Synergistic antiproliferative effects and induction of apoptosis 
were observed with combination therapy. The concentration of each agent in the 
combination was 50% less than the IC50 of each when used individually, which may 
result in improved tolerability when these agents are used clinically [11].
Building off these results, in [37], Falchi et al. presented a phase 1/2 trial with com-
bination therapy of romidepsin and 5-AZA in the treatment of lymphoma patients. 
10/30 patients in the study had TCLs. While the ORR for all 25 cohort patients evalu-
able for efficacy was 28% (7/25), with a 16% CRR (4/25), the 6 evaluable TCL patients 
demonstrated an 83% ORR (5/6) and a 50% CRR (3/6). Combination therapy was 
generally well tolerated: 5 dose limiting toxicities were recorded, including neutrope-
nia (2), thrombocytopenia (1), pleural effusion (1), and a missed dose (1). Five total 
patients experienced thrombocytopenia, with three experiencing febrile neutropenia.
4.2 TET2
The ten-eleven translocation (TET) family of proteins are dioxygenases which cat-
alyze DNA demethylation [38]. Aberrant demethylation has been linked to dysregula-
tion of molecules such as BCL6, the transcription factor involved in the differentiation 
of T helper cells [39]. Abnormal differentiation of these cells provides opportunities 
for them to obtain late cooperative mutations rendering them malignant. TET2 
mutations are frequently seen in mature TCLs [3]. In a study evaluating 190 TCL 
patients for TET2 mutations, 40/86 (47%) AITL patients carried the mutation, as did 
22/58 (38%) PTCL-NOS patients. No other forms of TCL carried the mutation in this 
sample (18 ALCL patients and 12 NKTL patients, among others). TET2 mutations 
have been shown to occur in up to 80% of AITL patients [23]. TET2 mutations are also 
associated with advanced disease and shorter progression free survival.
The development of TET2 inhibitors for TCLs is currently in pre-clinical stages. 
TCL patients with TET2 mutations frequently also display mutations in RHOA, a 
GTP-ase important in stem cell differentiation, cell migration and cell shape. The 
cooperation of these two mutations in TCL progression, and whether small molecule 
inhibitors can halt or reverse disease progression, is under investigation [40].
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4.3 IDH2
Changes in DNA methylation can occur indirectly, as a consequence of muta-
tion of isocitrate dehydrogenase (IDH) enzymes. IDH2 is a regulator of TET2, and 
mutations in IDH2 have been described in up to 45% of patients with AITL [3]. 
Biochemically, IDH2 catalyzes the conversion of isocitrate to 2-oxoglutarate (2OG). 
In AITL, mutant IDH2 generates (R)-2-hydroxyglutarate (2HG), an oxymetabo-
lite potentially contributing to malignant transformation through inhibition of 
2OG-dependent enzymes. These enzymes are involved in functions ranging from 
DNA and histone modification to cellular differentiation, thus primed to produce 
malignancy when abnormally regulated. AG-221, a, orally available small molecule 
inhibitor of IDH2, has been tested in phase 1 and 2 trials of patients with AITL and 
AML (NCT02273739) [3, 39]. Given the frequent co-occurrence of IHD2 and TET2 
mutations, combination therapy with inhibitors of each may have promise [41].
4.4 Bromodomain and extra-terminal (BET)
Bromodomain and extra-terminal (BET) proteins play a role in epigenetic mem-
ory and regulation of growth-promoting gene transcription [42]. BRD2, BRD3, 
BRD4, and testis-specific BRDT recognize acetylated lysine residues on histone tails 
and recruit transcriptional regulatory complexes to facilitate transcription of genes 
involved in cell cycle progression and apoptosis [43]. For instance, BRD4 regulates 
MYC transcription. OTX015, an oral BRD2/3/4 inhibitor, induced cell cycle arrest 
in 5/8 ALCL cell lines. ALK status had no impact on likelihood of response. OTX015 
was found to suppress the transcription of the MYC gene in 4/4 cell lines [44].
Amplifications of the MYC oncogene are common in CTCL, occurring in 42.5% 
of leukemic CTCLs. JQ1, a selective small molecule inhibitor of BET proteins, dose-
dependently decreased the cell number of CTCL cells through G1 cell cycle arrest 
and down-regulation of c-MYC expression. It also inhibited tumor growth of CTCL 
cells in vivo [45]. Several other types of BET inhibitors have been shown to induce 
dose-dependent decreases in viability of nine CTCL cell lines, and combining BET 
inhibitors with HDAC inhibitors potentiated this effect. Importantly, combina-
tion therapy was effective in cell lines from patients previously treated with other 
single therapies, including prior romidepsin monotherapy with relapse in one cell 
line. Significant reduction of BCL2 and MYC expression was seen in cells treated 
with combination therapy. Given that there is a 25% overlap in genes induced by 
BET inhibitors and HDAC inhibitors separately, it is theorized that the synergy of 
this combination therapy lies in the induction of HDAC-silenced genes, enabled 
by BET inhibition. Initial MYC amplification status was not found to be predictive 
of sensitivity to BET inhibition or the synergy of therapies used in combination. 
Finally, a functional interdependence between BRD4 and DOT1L in specific types 
of transcriptional regulation has been noted, suggesting a possible role for combi-
nation therapy involving inhibitors of these two molecules [3].
4.5 Anti-fols
The vitamin folate is essential as a source of the one carbon group required to 
methylate DNA. The folate pathway, and thus the 1-carbon pathway and DNA 
methylation is complex, built within it many checks and balances to maintain nor-
mal DNA methylation. Low folate status induced by diet or drugs can have “desta-
bilizing consequences,” resulting in impaired production of thymidine leading to 
uracil insertion in the DNA sequence, global DNA hypomethylation and ultimately 
chromosome instability and breakage.
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There are two forms of folate that can enter the body depending on the mode of 
consumption. Folate comes from natural food sources, and folic acid comes from sup-
plements or fortified foods. When folate enters the cell, it is metabolized to 5-methyl-
tetrahydrofoate (5-methyl THF). Folic acid however is first reduced to dihydrofolate 
by dihydrofolate reductase and then to tetrahydrofolate (THF). Polyglutamination of 
THF allows for cellular retention. After a series of steps, THF is converted to 5-methyl-
THF [46]. 5-Methyl THF is then converted to methionine and back to THF by methio-
nine synthase which acts as the 1-carbon donor for S-adenosylmethionine (SAM). 
SAM donates methyl groups to DNA via DNMT1, 3a, and 3b. We have discussed the 
role of DNMT inhibitors as effective therapy for TCLs and will now focus on inhibi-
tion of other pathways as a means of decreasing DNA methylation (Figure 2).
Methotrexate is a widely used antimetabolite utilized as an antineoplastic agent 
since the 1950s [47, 48]. It has been used for the treatment of CTCL and other T-cell 
lymphoproliferative disorders such as lymphomatoid papulosis. Patients are often 
treated with low doses in a metronomic fashion. Methotrexate is a folic acid ana-
logue and one of its actions is to block dihydrofolate reductase which disrupts the 
folic acid pathway. Evaluation in CTCL cell lines treated with methotrexate led to a 
decrease in SAM and subsequently decreased promoter region methylation leading 
to increase FAS protein expression. The addition of SAM was able to overcome the 
effects induced by methotrexate. Methotrexate, however, has not had the same 
success in the treatment of the more aggressive PTCL.
Pralatrexate is not merely a second-generation methotrexate. Although, similar 
to methotrexate, pralatrexate exerts its effects by inhibition of DHFR, it has higher 
affinity for the reduced folate carrier-1 (RFC-1) and has greater cellular retention 
through high a rate of forming polyglutamylated conjugates [49]. RFC-1 is an oncofe-
tal protein expressed mostly on the membranes of fetal and tumor cells. This allows 
some selectivity of pralatrexate for malignant cells over normal cells. Interestingly, 
pralatrexate has enhanced activity in TCL and to date across several clinical stud-
ies, the only B-cell lymphoma that has demonstrated sensitivity to pralatrexate is 
follicular lymphoma. TCLs and follicular lymphoma biology’s share the common 
feature of increased methylation of DNA and histone. One potential mechanism of 
action of pralatrexate, may be through modulation of methylation. Though not well 
Figure 2. 
Direct and indirect inhibition of DNA methylation. DNA methylation can be inhibited directly by inhibiting 
the DNMT enzymes with DNMT inhibitors azacitidine and decitabine. DNA methylation may be inhibited 
indirectly by decreasing the 1-carbon methyl donor pool. This can be accomplished via treatment with 
methotrexate or pralatrexate. Key: MTX, methotrexate; PDX, pralatrexate; DHF, dihydrofolate; THF, 
tetrahydrofolate; DHFR, dihydrofolate reductase; MS, methionine synthase; SAM, S-adenosylmethionine; 
SAH, S-adenosylhomocysteine; DNMT, DNA methyltransferase.
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understood, by inhibiting DHFR, the 1-carbon pathway may be disrupted. We have 
observed in our laboratory that treatment of TCL cell lines with pralatrexate does 
in fact lead to decreased SAM and increased SAH depleting the pool of 1-carbon 
methyl donors (unpublished data). These initial studies merit further investigation to 
validate whether this translates into modulation of DNA methylation.
Clinically, the combination of pralatrexate and romidepsin demonstrated an 
early signal of response for patient with TCL treated on a phase I clinical study [50]. 
Of the 14 patients with TCL that were evaluable for response, 10 (71%) achieved a 
response with a complete response rate achieved in 4/10 and a partial response in 
6/10 patients. Of the B-cell lymphoma patients only those with follicular lymphoma 
responded, with 3/4 follicular lymphomas achieving a partial remission. This 
combination may be acting as a dual epigenetic therapy of sorts, with pralatrex-
ate serving as the hypomethylating agent and romidepsin as the HDAC inhibitor. 
Thinking about anti-fols in this way, we may come to a new understanding of how 
to better utilize these old drugs (such as methotrexate) for new purposes.
5. Conclusion
As our understanding of the pathologic drivers of distinct subtypes of TCL grows, 
we are learning that epigenetic derangements play an important role in lympho-
magenesis. Some such derangements include mutations in TET2, IDH2, DNMT3A, 
EP300, and CBP. Collectively these mutations contribute to a chromatin silenced and 
chemo-resistant state. In the 10 years since the approval of HDAC inhibitors for TCL, 
there has been a burst in the creation of novel agents and the repurposing of others 
to target such biology in TCL. Many of these agents are already being studied in the 
clinical setting and the clinical application of these agents in TCL is beginning to be 
realized. The next steps will involve finding the most safe and effective combina-
tions that will best induce durable complete responses. These agents might be best 
utilized for discrete TCL subtypes, for example DNMT inhibitors for AITL and EZH2 
inhibitors for ATLL. Furthermore, as we now have an understanding that epigenetics 
is crucial to the development of these lymphomas, we need to understand how this 
intersects with immune function and the microenvironment as well as the metabolic 
disposition of these malignant cells. Answering some of these questions will enable 
finding the right partners for these drugs whether it be PI3K inhibitors, PD1 inhibi-
tors or BCL2 mimetics. As the field of targeted therapy for TCL grows, we now have 
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